Martin H. Huber Jr. bought stock once, on May 19, 2025

Martin H. Huber Jr., M.D., is a director of Syndax Pharmaceuticals Inc. (Nasdaq: SNDX) and a long‑time biotechnology and pharmaceutical executive with deep expertise in oncology drug development.( As a corporate insider at Syndax, he has reported multiple equity transactions in the company and is listed with the relationship of Director and potential 10% owner status in recent SEC Form 4 filings.( Dr. Huber brings more than two decades of experience spanning academic oncology, clinical research, and leadership roles in biopharmaceutical R&D.(

Dr. Huber currently serves on the boards of Syndax Pharmaceuticals Inc. and Mersana Therapeutics Inc., complementing a career that has included serving as President of R&D and Chief Medical Officer, and later President, at Xilio Therapeutics Inc., Senior Vice President and Chief Medical Officer at TESARO Inc., and Vice President, Oncology Clinical Research at Merck Research Laboratories.( Earlier in his career he held roles of increasing responsibility at Schering‑Plough, Hoffmann‑La Roche, and Rhone‑Poulenc Rorer, and was previously an Assistant Professor of Oncology at the University of Texas M.D. Anderson Cancer Center, reflecting a strong foundation in academic medicine.( He earned his M.D. from Baylor College of Medicine, following a B.S. in biology from Texas Lutheran College, and completed his medical oncology training at U.T. M.D. Anderson Cancer Center, establishing the clinical and scientific background that underpins his leadership in oncology drug development.(

Written by Perplexity from public sources.